Compare ICU & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICU | EVGN |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 9.6M |
| IPO Year | N/A | 2013 |
| Metric | ICU | EVGN |
|---|---|---|
| Price | $4.37 | $0.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | ★ 118.5K | 44.1K |
| Earning Date | 05-14-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.00 | N/A |
| Revenue Next Year | $50.00 | $73.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.72 |
| 52 Week High | $4.93 | $2.42 |
| Indicator | ICU | EVGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 40.06 |
| Support Level | $2.26 | $0.73 |
| Resistance Level | $4.89 | $1.23 |
| Average True Range (ATR) | 0.41 | 0.06 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 66.67 | 10.66 |
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.